Net sales rose 18% in Q2 2026, with strong organic and acquisition-driven growth, and adjusted EBITA up 24% to SEK 471m. All business areas contributed, margins improved, and cash flow was robust, supporting ongoing acquisitions and a stable outlook.Original document: Asker Healthcare Group AB [ASK…
Net sales rose 18% in Q2 2026, with strong organic and acquisition-driven growth, and adjusted EBITA up 24% to SEK 471m. All business areas contributed, margins improved, and cash flow was robust, supporting ongoing acquisitions and a stable outlook.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.